Equity Research, Broker Reports, and media content on MORPHOSYS AG

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about MORPHOSYS AG
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on MORPHOSYS AG. We currently have 3 research reports from 1 professional analysts.

Open
48.9
Volume
0.1m
Range
48.9/49.7
Market Cap
1,436,555,805m
52 Week
32.9/52.0
Date Source Announcement
13Dec16 06:30 GNW MorphoSys Starts Phase 2 Trial of MOR208 in Combination with Idelalisib in Patients with Relapsed or Refractory CLL or SLL Previously Treated with a BTK Inhibitor
06Dec16 06:30 GNW MorphoSys Presents Updated Clinical Results for Anti-CD38 Antibody MOR202 at ASH 2016
06Dec16 06:30 GNW MorphoSys Presents Updated Clinical Data for Blood Cancer Candidate MOR208 in NHL and CLL at ASH 2016 Conference:
28Nov16 11:07 GNW MorphoSys Announces That Its Licensee Janssen Has Submitted a Marketing Authorisation Application For Guselkumab in Europe
17Nov16 13:46 GNW MorphoSys Announces That Its Licensee Janssen Has Submitted Biologics License Application For Guselkumab
15Nov16 22:35 GNW MorphoSys Raises EUR 115 million in Private Placement
15Nov16 22:34 GNW Ad hoc: MorphoSys Raises EUR 115 million in Private Placement
  • Frequency of research reports

     

  • Research reports on

    MORPHOSYS AG

  • Providers covering

    MORPHOSYS AG

Latest Content

View the latest research, videos, and podcasts for this company.